High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

Blood

Volumn 113, Issue 22, 2009, Pages 5583-5587

  Preudhomme, Claude ^a,b,c   Renneville, Aline ^a,b,c   Bourdon, Violaine ^d   Philippe, Nathalie ^a,b,c   Roche Lestienne, Catherine ^a   Boissel, Nicolas ^e   Dhedin, Nathalie ^f   André, Jean Marie ^g   Cornillet Lefebvre, Pascale ^h   Baruchel, André ⁱ   Mozziconacci, Marie Joelle ^d   Sobol, Hagay ^d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c North West Canceropole   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL DEBROUSSE   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLELE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CHILD; CLINICAL ARTICLE; DISEASE COURSE; FAMILIAL PLATELET DISORDER; FEMALE; GENE; GENE DUPLICATION; GERM LINE; HUMAN; MALE; POINT MUTATION; PRIORITY JOURNAL; RUNX1 GENE; SCHOOL CHILD; THROMBOCYTOPATHY; TRISOMY 21; CASE REPORT; FAMILY; GENE FREQUENCY; GENETICS; HOMOZYGOTE; MIDDLE AGED; PEDIGREE; PRECANCER; THROMBOCYTE DISORDER;

RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1;

ADULT; BLOOD PLATELET DISORDERS; CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FAMILY; FEMALE; GENE FREQUENCY; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PEDIGREE; PRECANCEROUS CONDITIONS; YOUNG ADULT;

EID: 67049162141     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168260     Document Type: Article

References (25)

1. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-175.
2. Michaud J, Wu J, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-1372.
3. Ganly P, Walker LC, Morris CM. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leuk Lymphoma. 2004;45:1-10. (Pubitemid 38181387)
4. Kirito K, Sakoe K, Shinoda D, et al. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. Haematologica. 2008;93:155-156. (Pubitemid 351156172)
5. Owen C, Barnett Fitzgibbon J. Familial myelodysplasia and acute myeloid leukemia-a review. Br J Haematol. 2008;140:123-132. (Pubitemid 350265048)
6. Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy (FPD/AML). Blood. 2008; 112:4639-4645.
7. Béri-Dexheimer M, Latger-Cannard V, Philippe C, et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet. 2008;16: 1014-1018.
8. Minelli A, Maserati E, Rossi G, et al. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies. Genes Chromosomes Cancer. 2004;40:165-171. (Pubitemid 38703094)
9. International System for Cytogenetic Nomenclature. Guidelines for Cancer Cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature. Memphis, TN: Felix Mitelmann, 1995.
10. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005; 106:3618-3620. (Pubitemid 41609201)
11. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.
12. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11:1447-1452. (Pubitemid 27404383)
13. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439. (Pubitemid 32291491)
14. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56:1418-1425.
15. Callens C, Chevret S, Cayuela JM, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153-1160. (Pubitemid 40945998)
16. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20: 965-970.
17. Shinawi M, Erez A, Shardy DL, et al. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood. 2008;112:1042-1047.
18. Rothenberg EV, Taghon T. Molecular genetics of T-cell development. Annu Rev Immunol. 2005;23: 601-649.
19. Ono M, Yaguchi H, Ohkura N, et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007;446:685-689. (Pubitemid 46606883)
20. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10:299-304. (Pubitemid 38667622)
21. Roumier C, Fenaux P, Lafage M, et al. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia. 2003;17:9-16. (Pubitemid 36175882)
22. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152. (Pubitemid 34977210)
23. Roche-Lestienne C, Deluche L, Corm S, et al. RUNX1 DNA-binding mutations and RUNX1- PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008;111:3735-3741.
24. Pedersen-Bjergaard J, Andersen MK, Andersen MT, et al. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22:240-248. (Pubitemid 351250527)
25. Pabst T, Eyholzer M, Haefliger S, et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol. 2008; 26:5088-5093.